PCNA and Ki-67 in endometrial hyperplasias and evaluation of the potential of malignancy

Objective: The aim of this study was to investigate malignancy potential in endometrial hyperplasias and association with PCNA and Ki-67. Methods: Hysterectomy or probe curettage materials of 62 patients (20 simple hyperplasias (SH), six SH with atypical changes, five complex hyperplasias (CH), 11 CH with atypical changes, ten proliferative endometrium (PE) and ten secretory endometrium) were included in our study. Immunohistochemical staining for PCNA and Ki-67 protein was performed on formalinfixed and paraffin-embedded tissue samples. Results: Immunoreactivity of PCNA was found to be significantly higher in atypical CH as compared to all other groups (p < 0.05). Also immunoreactivity of PCNA was significantly lower in SH as compared to atypical CH, and PE (p < 0.05). Average values showed that Ki-67 immunoreactivity is highest for atypical CH, and PE. Immunoreactivity of Ki-67 was found to be significantly higher in atypical CH as compared to other groups except PE (p < 0.05). Conclusion: PCNA immunoreactivity can be useful in patients with endometrial CH showing mild or moderate atypical changes in terms of prefering more conservative treatment modalities in those with low PCNA index. Also we suggest that Ki-67 could be insufficient to determine the potential of malignancy.

Endometrial hyperplasia; Endometrial carcinoma; PCNA; Ki-67

[1] Wingo P.A., Tong T., Bolden S.: “Cancer Statistics, 1995”. C.A. Cancer J. Clin., 1995, 45, 8.

[2] Kurman R.J., Kaminski P.F., Norris H.J.: “The behavior of endometrial hyperplasia: a long term study of untreated hyperplasia in 170 patients”. Cancer, 1985, 56, 403.

[3] Montgomery B.E., Daum G.S., Dunton C.J.: “Endometrial hyperplasia: A Review”. Obstet. Gynocol. Surv., 2004, 59, 368.

[4] Huang S.J., Ampara E.G., Fu Y.S.: “Endometrial hyperplasia: Histologic classification and behaviour”. Sung. Pathol., 1988, 1, 215.

[5] Snider D.D., Stuart G.C., Nation J.G., Robertson D.I.: “Evaluation of surgical staging in stage 1 low malignant potential ovarian tumors”. Gynecol. Oncol., 1991, 40, 129.

[6] Lewis E., Wallace W.S.: “Radiologic diagnosis of ovarian cancer”. In: Piver M.S., (ed.): “Ovarian malignancies”. Edinburgh, Churchill Livingstone, 1987, 59.

[7] Pickartz H., Beckmann R., Fleige B., Due W., Gerdes J., Stein H.: “Steroid receptors and proliferative activity in non-neoplastic and neoplastic endometria”. Virchows Arch. A Pathol. Anat. Histopathol., 1990, 417, 163.

[8] Gerdes J., Lemke H., Baisch H., Wacker H.-H., Schwab U., Stein H.: “Cell cycle analysis of a cell proliferation associated human nuclear antigen defined by the monoclonal antibody Ki-67”. J. Immunol., 1984, 133, 1710.

[9] Keshgegian A.A., Cnaan A.: “Proliferation markers in breast carcinoma. Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1”. Am. J. Clin. Pathol., 1995, 104, 42.

[10] Miyachi K., Fritzler M.J., Tan E.M.: “Autoantibody to a nuclear antigen in proliferating cells”. J. Immunol., 1978, 121, 2228.

[11] Ogata K., Kurki P., Celis J.E., Nakamura R.M., Tan E.M.: “Monoclonal antibodies to a nuclear protein (PCNA/cyclin) associated with DNA replication”. Exp. Cell. Res., 1987, 168, 475.

[12] Iachino C., Katsikoyiannis N., Dallera F.: “Assessment of proliferating cell nuclear antigen (PCNA) immunoreactivity in exocrine pancreatic carcinomas”. Pathologica, 1995, 87, 56.

[13] Scott R.J., Hall P.A., Haldane J.S., van Noorden S., Price Y., Lane D. P., Wright N.A.: “A comparison of immunohistochemical markers of cell proliferation with experimentally determined growth fraction”. J. Pathol., 1991, 165, 173.

[14] Sasano H., Date F., Miyazaki S.: “Correlation of c-myc exspression and cell proliferation in human stomach cancer. A study employing PCNA”. Jpn. J. Cancer Res., proceedings of Jpn Cancer Assoc., 1991, 129, 704.

[15] Sasano H., Watanabe K., Ito K., Sato S., Yajima A.: “New concepts in the diagnosis and prognosis of endometrial carcinoma”. Pathol. Annu., 1994, 29, 31.

[16] Ito K., Sasano H., Watanabe K., Ozawa N., Sato S., Yajima A.: “Immunohistochemical study of PCNA (proliferating cell nuclear antigen) in normal and abnormal endometrium”. Int. J. Gynecol. Cancer, 1993, 3, 122.

[17] Yu C.C., Wilkinson N., Brito M.J., Buckley C.H., Fox H., Levison D. A.: “Patterns of immunohistochemical staining for proliferating cell nuclear antigen and p53 in benign and neoplastic human endometrium”. Histopathology, 1993, 23, 367.

[18] Cinel L., Polat A., Aydın O., Düsmez D., Eilmez R.: “Bcl-2, iNOS, p53 and PCNA expression in normal, disordered proliferative, hyperplastic and malignant endometrium”. Pathol. Int., 2002, 52, 384.

[19] Terlikowski S., Lenczewski A., Famulski W., Sulkowska M., Kulikowski M.: “Proliferative activity in endometrial hyperplasia and adenocarcinoma”. Folia Histochem Cytobiol., 2001, 39, 163.

[20] Keshgegian A.A., Cnaan A.: “Proliferation markers in breast carcinoma. Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1”. Am. J. Clin. Pathol., 1995, 104, 42.

[21] Weikel W., Brumm C., Wilkens C., Beck T., Knapstein P.G.: “Growth fractions (Ki-67) in primary breast cancers with particular reference to node-negative tumors”. Cancer Detect. Prev., 1995, 19, 446.

[22] Molino A., Micciolo R., Turazza M., Bonetti F., Piubello Q., Bonetti A. et al.: “GL. Ki-67 immunostaining in 322 primary breast cancers: associations with clinical and pathological variables and prognosis”. Int. J. Cancer, 1997, 74, 433.

[23] Risberg B., Karlsson K., Abeler V., Lagrelius A., Davidson B., Karlsson M.G.: “Dissociated expression of Bcl-2 and Ki-67 in endometrial lesions: diagnostic and histogenetic implications”. Int.

J. Gynecol. Pathol., 2002, 21, 155.

[24] Ambros R.A.: “Simple hyperplasia of the endometrium: an evaluation of proliferative activity by Ki-67 immunostaning”. Int. J. Gynecol. Pathol., 2000, 19, 206.

[25] Ioffe O.B., Papadimitriou J.C., Drachenberg C.B.: “Correlation of proliferative indices, apoptosis and related oncogene ekspression (bcl-2 and c-erB-2) and p53 in proliferative, hyperplastic and malignant endometrium”. Human. Pathol., 1998, 29, 1150.